India, Aug. 11 -- Zydus Lifesciences Limited has received final approval from the US Food and Drug Administration (USFDA) to market Diltiazem Hydrochloride Tablets USP in strengths of 30 mg, 60 mg, 90 mg, and 120 mg (reference listed drug: Cardizem®).
The medication, a calcium-channel blocker, is indicated for the management of chronic stable angina and angina caused by coronary artery spasm. It works by relaxing blood vessels, reducing the heart's workload, and improving blood and oxygen supply to the heart muscle.
The product will be manufactured at Zydus Lifesciences' facility in Baddi, Himachal Pradesh. According to IQVIA MAT (June 2025), Diltiazem Hydrochloride Tablets had annual U.S. sales of USD 13.9 million.
With this approva...